Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.
4D Molecular Therapeutics Inc. (FDMT) is a clinical-stage biotechnology company pioneering targeted gene therapies through its proprietary AAV vector platform. This page serves as the definitive source for FDMT news, providing investors and researchers with timely updates on therapeutic advancements across ophthalmology, pulmonology, and cardiology.
Access official press releases and curated analysis covering clinical trial progress, regulatory milestones, and scientific innovations. Our repository includes updates on key programs like 4D-150 for retinal diseases and 4D-710 for cystic fibrosis, along with strategic partnerships advancing next-generation genetic medicines.
All content is rigorously verified to ensure accurate reporting on FDMT's Therapeutic Vector Evolution platform and its applications. Bookmark this page to monitor developments in engineered gene delivery systems and their potential to address unmet medical needs through durable single-dose therapies.
4D Molecular Therapeutics (Nasdaq: FDMT) will present interim data from the Phase 1/2 AEROW clinical trial of aerosolized 4D-710 for cystic fibrosis lung disease at the 47th European Cystic Fibrosis Conference on June 6, 2024. Dr. Jennifer L. Taylor-Cousar will present the data at 5:00 p.m. BST. The company will also host a webcast to discuss the data and provide a program update on the same day at 8:00 a.m. ET.
The presentation, titled 'CFTR transgene expression in airway epithelial cells following aerosolized administration of the AAV-based gene therapy 4D-710 to adults with cystic fibrosis lung disease,' will be part of the session 'Where are we with new therapeutic approaches?'
The webcast will be archived on the 4DMT website for one year.
4DMT reported positive interim data from the PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients, advancing into Phase 3 by Q1 2025. They presented 24-week analysis from the Population Extension cohort and Phase 1/2 AEROW trial at upcoming conferences. Additionally, they completed a public follow-on offering raising $337 million, ensuring cash runway into H1 2027.
4D Molecular Therapeutics, a leading genetic medicines company, will participate in an investor conference in May. The management team will conduct a fireside chat and be available for one-on-one meetings. The presentation will take place on May 14, 2024, at the Bank of America Health Care Conference.
4DMT, a genetic medicines company, announced presentations at the 2024 ARVO Annual Meeting, including interim results from the PRISM Phase 2 trial for 4D-150 and preclinical data on 4D-175. The Company aims to treat diseases like AMD through genetic medicine.
FAQ
What is the current stock price of 4D Molecular Therapeutics (FDMT)?
What is the market cap of 4D Molecular Therapeutics (FDMT)?
